Pediatric neuromyelitis optica spectrum disorders in Portugal: A multicentre retrospective study.

[1]  Jacqueline A Palace,et al.  Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis optica spectrum disorders , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[2]  F. Palavra,et al.  Neuromyelitis optica spectrum disorders: A nationwide Portuguese clinical epidemiological study. , 2021, Multiple sclerosis and related disorders.

[3]  C. Lechner,et al.  E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. , 2020, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[4]  E. Yeh,et al.  Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis , 2020, Frontiers in Pediatrics.

[5]  Jae-Won Hyun,et al.  Value of Area Postrema Syndrome in Differentiating Adults With AQP4 vs. MOG Antibodies , 2020, Frontiers in Neurology.

[6]  K. Rostásy,et al.  Epidemiology of Pediatric NMOSD in Germany and Austria , 2020, Frontiers in Neurology.

[7]  F. Paul,et al.  MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. , 2018, Multiple sclerosis and related disorders.

[8]  Jacqueline A Palace,et al.  MOG-Enzephalomyelitis: Internationale Empfehlungen zu Diagnose und Antikörpertestung , 2018, Der Nervenarzt.

[9]  O. Ciccarelli,et al.  Myelin oligodendrocyte glycoprotein and aquaporin‐4 antibodies are highly specific in children with acquired demyelinating syndromes , 2018, Developmental medicine and child neurology.

[10]  O. Ciccarelli,et al.  Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease , 2018, JAMA neurology.

[11]  Jacqueline Palace,et al.  Clinical presentation and prognosis in MOG-antibody disease: a UK study , 2017, Brain : a journal of neurology.

[12]  K. Rostásy,et al.  Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome , 2017, Neurology.

[13]  B. Weinshenker,et al.  Neuromyelitis Spectrum Disorders , 2017, Mayo Clinic proceedings.

[14]  S. Pittock,et al.  Association of Extension of Cervical Cord Lesion and Area Postrema Syndrome With Neuromyelitis Optica Spectrum Disorder , 2017, JAMA neurology.

[15]  K. Rostásy,et al.  Neuromyelitis optica spectrum disorders in children and adolescents , 2016, Neurology.

[16]  Cody S. Olsen,et al.  Clinical features of neuromyelitis optica in children , 2016, Neurology.

[17]  K. Rostásy,et al.  Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[18]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[19]  Jacqueline A Palace,et al.  Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. , 2014, JAMA neurology.

[20]  Jacqueline A Palace,et al.  Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. , 2013, JAMA neurology.

[21]  M. Papadopoulos,et al.  Aquaporin 4 and neuromyelitis optica , 2012, The Lancet Neurology.

[22]  P. Vermersch,et al.  Long-term follow-up of neuromyelitis optica with a pediatric onset , 2010, Neurology.

[23]  B. Weinshenker,et al.  CNS aquaporin-4 autoimmunity in children , 2008, Neurology.

[24]  A. Bar-Or,et al.  Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders , 2008, Neurology.

[25]  Y. Fragoso,et al.  Neuromyelitis optica with onset in childhood and adolescence. , 2014, Pediatric neurology.